Akeso, Inc.

Akeso, Inc. is a publicly listed Chinese biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative antibody drugs. Headquartered in Zhongshan, Guangdong, China, the company's mission is to develop first-in-class and best-in-class new drugs, providing affordable therapeutic antibodies to patients worldwide, with the aim of becoming a leading global biopharmaceutical enterprise.

The company maintains a robust pipeline of over 50 innovative assets, with 27 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies and bispecific antibody-drug conjugates (ADCs). Key approved products include cadonilimab (a PD-1/CTLA-4 bispecific antibody), ivonescimab (a PD-1/VEGF bispecific antibody), penpulimab (a PD-1 inhibitor), ebronucimab (a PCSK9 inhibitor), and ebdarokimab (an IL-12/IL-23 inhibitor). Akeso focuses on addressing unmet clinical needs in major diseases, particularly within oncology, autoimmune diseases, inflammation, and metabolic disorders.

Led by co-founder, Chairwoman, President, and CEO Michelle Xia, Akeso has achieved significant milestones in its market positioning. Notably, its ivonescimab has received multiple authoritative updates and upgrades in the 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for Non-Small Cell Lung Cancer (NSCLC), solidifying its status as a new standard of care. In April 2025, the U.S. Food and Drug Administration (FDA) approved Akeso's Penpulimab, marking the company's first product to receive U.S. regulatory approval. Akeso is also advancing its ADC strategy, with its first ADC drug, AK138D1, entering Phase I clinical trials in Australia in February 2025. The company is recognized as the only global biopharmaceutical firm with two approved bispecific checkpoint antibodies for cancer immunotherapy.